JPRN-jRCT2080224105已完成3 期
Phase III study for evaluating efficacy and safety of a combination treatment of IDEC-C2B8 with steroid pulse therapy and plasmapheresis for antibody-mediated rejection after kidney transplant.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients who develop or suspect ABMR requiring treatment with IDEC-C2B8.
- •2.Patients who are 16 years and over at giving written informed consent.
- •3.Patients or Patient's representative who are able to understand the study protocol and provide the written informed consent.
排除标准
- •1.Patients who have a history of hypersensitivity or severe allergic to murine products.
研究者
相似试验
已完成
3 期
Phase III study for evaluating efficacy and safety of desensitization based on IDEC-C2B8 in living donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody. Phase III study for evaluating efficacy, safety and pharmacokinetics of pre-transplant administration of FK506 or FK506E(MR4) for 7 to 28 days in living donor kidney transplantation recipients.iving donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody.JPRN-jRCT2080224107ZENYAKU KOGYO CO., LTD.23
进行中（未招募）
1 期
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableMedDRA version: 18.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2015-002653-35-IERegeneron Pharmaceuticals, Inc.330
进行中（未招募）
1 期
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableAtopic dermatitisEUCTR2015-002653-35-NLRegeneron Pharmaceuticals, Inc.330
进行中（未招募）
1 期
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableMedDRA version: 19.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2015-002653-35-BERegeneron Pharmaceuticals, Inc.330
进行中（未招募）
1 期
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisableMedDRA version: 19.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2015-002653-35-ESRegeneron Pharmaceuticals, Inc.330